论文信息 - Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial. - 字舞流文

Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial.

Deepak L. Bhatt | R. Diaz | H. White | A. Budaj | J. Jukema | R. Lopes | S. Goodman | R. Harrington | V. Bittner | P. Steg | G. Schwartz | M. Szarek | Y. Poulouin | R. Pordy | P. Guimarães | A. Dalby | Megan Loy | R. Kiss

[1] R. Holman,et al. Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. , 2019, International journal of cardiology.

[2] J Wouter Jukema,et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018, The New England journal of medicine.

[3] A. Keech,et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[4] Wen-tong Fang,et al. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. , 2012, British journal of clinical pharmacology.

[5] P. Armstrong,et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. , 2009, European heart journal.